Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmaceutical Equivalents01:26

Pharmaceutical Equivalents

274
As defined by regulatory standards, pharmaceutical equivalents require generic drug products to have identical dosage forms and chemically identical active pharmaceutical ingredients (APIs). They must adhere to compendial or applicable standards for potency, content uniformity, disintegration times, and dissolution rates. In the case of modified-release dosage forms, variations in drug content are permissible as long as the delivered amount remains consistent with the innovator drug product.
274
Insulin: Biosynthesis, Chemistry, and Preparation01:25

Insulin: Biosynthesis, Chemistry, and Preparation

2.1K
The endoplasmic reticulum (ER) of pancreatic β-cells synthesizes preproinsulin, which consists of a signal peptide, A and B chains, and a C-peptide. Preproinsulin is then cleaved and folded into proinsulin, which translocates to the Golgi apparatus for sorting and packaging into secretory granules. In these granules, enzymatic clipping generates insulin and C-peptide.
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
2.1K
Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence01:27

Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence

226
Changes in polymorphic forms can significantly influence the bioavailability of poorly soluble drugs. Although the FDA defines pharmaceutical equivalence based on having the same active ingredient, dosage form, and route of administration, it does not automatically disqualify products with different polymorphic forms. This means two products with different polymorphs can still be deemed pharmaceutically equivalent. However, polymorphic differences can affect properties like wettability,...
226
Pharmaceutical Alternatives: Excipients and Impurities-Related Therapeutic Nonequivalence01:19

Pharmaceutical Alternatives: Excipients and Impurities-Related Therapeutic Nonequivalence

241
Pharmaceutical products contain more than just the active drug; they also contain various excipients such as binders, solubilizers, stabilizers, preservatives, and other elements. In some cases, impurities or contaminants might be present. Traditionally, quality control in pharmaceuticals has primarily focused on the analysis of the active drug, often overlooking the impact of these additional components. The recent issue with heparin contamination by over-sulfated chondroitin sulfate, a...
241
Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence01:22

Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence

259
Generic intravenous (IV) drugs are considered bioequivalent to their branded counterparts due to their 100% bioavailability upon administration. However, variations in stability among different drug products can significantly influence their therapeutic performance, even if they are pharmaceutically equivalent.Cefuroxime, a prophylactic antimicrobial, is often used as a single-dose IV injection for patients undergoing coronary artery bypass grafting surgery. A 3 g dose typically provides...
259
Modified-Release Drug Delivery Systems: Rate-Programmed I01:22

Modified-Release Drug Delivery Systems: Rate-Programmed I

172
Rate-programmed drug delivery systems (DDS) are designed to release drugs at specific, controlled rates to maintain consistent therapeutic levels. These systems are categorized based on their release mechanisms, including dissolution-controlled DDS, diffusion-controlled DDS, and combined dissolution-diffusion-controlled DDS.In dissolution-controlled DDS, the release rate depends on the slow dissolution of the drug itself or the surrounding matrix. Drugs with inherently slow dissolution rates,...
172

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Diverse organic molecules on Mars revealed by the first SAM TMAH experiment.

Nature communications·2026
Same author

Distribution of extraterrestrial nucleobases, other N-heterocycles, and their precursors in a sample from asteroid Bennu.

Communications chemistry·2026
Same author

Multiple formation pathways for amino acids in the early Solar System based on carbon and nitrogen isotopes in asteroid Bennu samples.

Proceedings of the National Academy of Sciences of the United States of America·2026
Same author

Does the Measured Abundance Suggest a Biological Origin for the Ancient Alkanes Preserved in a Martian Mudstone?

Astrobiology·2026
Same author

Nitrogen- and oxygen-rich organic material indicative of polymerization in pre-aqueous cryochemistry on Bennu's parent body.

Nature astronomy·2025
Same author

Prebiotic organic compounds in samples of asteroid Bennu indicate heterogeneous aqueous alteration.

Proceedings of the National Academy of Sciences of the United States of America·2025
Same journal

Crystal structure of 1-(piperidin-1-yl)butane-1,3-dione.

Acta crystallographica. Section E, Structure reports online·2015
Same journal

Crystal structure of methyl 1-methyl-3,5-diphenyl-7-tosyl-3,6,7,11b-tetra-hydro-pyrazolo-[4',3':5,6]pyrano[3,4-c]quinoline-5a(5H)-carboxyl-ate.

Acta crystallographica. Section E, Structure reports online·2015
Same journal

Crystal structure of 4-amino-1-(4-methyl-benz-yl)pyridinium bromide.

Acta crystallographica. Section E, Structure reports online·2015
Same journal

Crystal structure of (Z)-3-benz-yloxy-6-[(2-hy-droxy-anilino)methyl-idene]cyclo-hexa-2,4-dien-1-one.

Acta crystallographica. Section E, Structure reports online·2015
Same journal

Crystal structure of bis-(1-benzyl-1H-1,2,4-triazole) perchloric acid monosolvate.

Acta crystallographica. Section E, Structure reports online·2015
Same journal

Crystal structure of 2-(di-phenyl-phos-phanyl)phenyl 4-(hy-droxy-meth-yl)benzoate.

Acta crystallographica. Section E, Structure reports online·2015
See all related articles

Related Experiment Video

Updated: May 3, 2026

Solubility of Hydrophobic Compounds in Aqueous Solution Using Combinations of Self-assembling Peptide and Amino Acid
05:08

Solubility of Hydrophobic Compounds in Aqueous Solution Using Combinations of Self-assembling Peptide and Amino Acid

Published on: September 20, 2017

15.6K

Isovaline monohydrate.

Ray J Butcher1, Greg Brewer2, Aaron S Burton3

  • 1Department of Chemistry, Howard University, 525 College Street NW, Washington, DC 20059, USA.

Acta Crystallographica. Section E, Structure Reports Online
|January 24, 2014
PubMed
Summary
This summary is machine-generated.

This study details a valine isomer, a non-proteinogenic amino acid lacking an alpha-hydrogen. Its crystal structure reveals extensive hydrogen bonding forming a 3D network with water molecules.

More Related Videos

Preparation of Quality Inositol Pyrophosphates
10:34

Preparation of Quality Inositol Pyrophosphates

Published on: September 3, 2011

14.9K
An Efficient Method for the Synthesis of Peptoids with Mixed Lysine-type/Arginine-type Monomers and Evaluation of Their Anti-leishmanial Activity
12:02

An Efficient Method for the Synthesis of Peptoids with Mixed Lysine-type/Arginine-type Monomers and Evaluation of Their Anti-leishmanial Activity

Published on: November 2, 2016

14.4K

Related Experiment Videos

Last Updated: May 3, 2026

Solubility of Hydrophobic Compounds in Aqueous Solution Using Combinations of Self-assembling Peptide and Amino Acid
05:08

Solubility of Hydrophobic Compounds in Aqueous Solution Using Combinations of Self-assembling Peptide and Amino Acid

Published on: September 20, 2017

15.6K
Preparation of Quality Inositol Pyrophosphates
10:34

Preparation of Quality Inositol Pyrophosphates

Published on: September 3, 2011

14.9K
An Efficient Method for the Synthesis of Peptoids with Mixed Lysine-type/Arginine-type Monomers and Evaluation of Their Anti-leishmanial Activity
12:02

An Efficient Method for the Synthesis of Peptoids with Mixed Lysine-type/Arginine-type Monomers and Evaluation of Their Anti-leishmanial Activity

Published on: November 2, 2016

14.4K

Area of Science:

  • Crystallography
  • Biochemistry
  • Organic Chemistry

Background:

  • The study investigates a specific isomer of valine, a compound with the chemical formula C5H11NO2·H2O.
  • This isomer is distinct from the 20 proteinogenic amino acids essential for biological systems.
  • A key difference is the absence of an alpha-hydrogen atom, distinguishing it from natural amino acids.

Purpose of the Study:

  • To characterize the crystal structure and hydrogen bonding of a valine isomer monohydrate.
  • To understand the intermolecular interactions in the solid state for this non-proteinogenic amino acid.

Main Methods:

  • Crystallization from water to obtain the monohydrate form.
  • Analysis of the crystal structure, including hydrogen bonding interactions.

Main Results:

  • The compound crystallizes as a zwitterion monohydrate.
  • Extensive hydrogen bonding was observed, including interactions between water molecules and carboxylate/amine groups.
  • Intermolecular hydrogen bonds between carboxylate and amine groups form a three-dimensional network.

Conclusions:

  • The valine isomer forms a stable 3D hydrogen-bonded network in its crystalline monohydrate form.
  • The structural characterization provides insights into the behavior of non-proteinogenic amino acids.